Cargando…

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

BACKGROUND: Approximately half of tumor cell lines are resistant to the tumor-selective apoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (Apo22L/TRAIL). Previously, we showed that combining Apo2L/TRAIL with sorafenib, a multikinase inhibitor, results in dramatic efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdulghani, Junaid, Allen, Joshua E., Dicker, David T., Liu, Yingqiu Yvette, Goldenberg, David, Smith, Charles D., Humphreys, Robin, El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784419/ https://www.ncbi.nlm.nih.gov/pubmed/24086526 http://dx.doi.org/10.1371/journal.pone.0075414

Ejemplares similares

Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
por: Singh, Kamini, et al.
Publicado: (2014)

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL
por: Cheung, Vanessa, et al.
Publicado: (2013)

Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey
por: Zuch de Zafra, Christina L, et al.
Publicado: (2016)

A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents
por: Arizono, Y, et al.
Publicado: (2003)

Apigenin Sensitizes Prostate Cancer Cells to Apo2L/TRAIL by Targeting Adenine Nucleotide Translocase-2
por: Oishi, Masakatsu, et al.
Publicado: (2013)

Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts
por: El-Zawahry, Ahmed, et al.
Publicado: (2005)

Regulation of the human TRAIL gene
por: Allen, Joshua E., et al.
Publicado: (2012)

The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
por: Hylander, Bonnie L, et al.
Publicado: (2005)

A Novel Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells
por: van Valen, Frans, et al.
Publicado: (2012)

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
por: Allen, Joshua E, et al.
Publicado: (2015)

Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy
por: Bouralexis, S, et al.
Publicado: (2003)

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
por: Ray, Jocelyn E., et al.
Publicado: (2021)

Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
por: Pan, Y, et al.
Publicado: (2011)

Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma Cells
por: Zhang, Shuijun, et al.
Publicado: (2012)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

TRAIL Deficiency Contributes to Diabetic Nephropathy in Fat-Fed ApoE(-/-) Mice
por: Cartland, Siân P., et al.
Publicado: (2014)

Dihydroartemisinin Enhances Apo2L/TRAIL-Mediated Apoptosis in Pancreatic Cancer Cells via ROS-Mediated Up-Regulation of Death Receptor 5
por: Kong, Rui, et al.
Publicado: (2012)

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
por: Wagner, Jessica, et al.
Publicado: (2015)

Correction: Dihydroartemisinin Enhances Apo2L/TRAIL-Mediated Apoptosis in Pancreatic Cancer Cells via ROS-Mediated Up-Regulation of Death Receptor 5
por: Kong, Rui, et al.
Publicado: (2012)

Cosmc transfection decreases malignant behavior of Tn(+) cells and enhances sensitivity to apoptosis when induced by Apo2L/TRAIL via alteration of O-glycan structure
por: Ding, Ruisong, et al.
Publicado: (2021)

Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis
por: Murphy, Á. C., et al.
Publicado: (2013)

Therapeutic targeting of TRAIL death receptors
por: Di Cristofano, Francesca, et al.
Publicado: (2023)

Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe(−/−) Mice
por: Tang, Yang, et al.
Publicado: (2020)

Thymus hirtus sp. algeriensis Boiss. and Reut. volatile oil enhances TRAIL/Apo2L induced apoptosis and inhibits colon carcinogenesis through upregulation of death receptor pathway
por: Guesmi, Fatma, et al.
Publicado: (2021)

Endogenous Bak inhibitors Mcl-1 and Bcl-x(L): differential impact on TRAIL resistance in Bax-deficient carcinoma
por: Gillissen, Bernhard, et al.
Publicado: (2010)

TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
por: Staniek, Julian, et al.
Publicado: (2019)

Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif
por: Ultsch, Mark, et al.
Publicado: (2021)

TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
por: Karl, I, et al.
Publicado: (2014)

TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
por: Karl, I, et al.
Publicado: (2014)

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
por: Trivedi, Rachana, et al.
Publicado: (2015)

The SCF(Skp2) ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L)
por: Roberts, Jamie Z., et al.
Publicado: (2020)

Age and APOE affect L-carnitine system metabolites in the brain in the APOE-TR model
por: Huguenard, Claire J. C., et al.
Publicado: (2023)

TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill
por: Mohr, Andrea, et al.
Publicado: (2015)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
por: Tuthill, Mark H, et al.
Publicado: (2014)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
por: REFAAT, ALAA, et al.
Publicado: (2014)

SURVIVAL ADVANTAGE OF APOE2
por: Seshadri, Sudha
Publicado: (2019)

Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
por: Hendriks, Djoke, et al.
Publicado: (2016)

N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
por: Dufour, Florent, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s81os8k1vphc7sl6pe5esfeelb